Scholarlink

Purpose <p>Systemic therapy is standard for metastatic inflammatory breast cancer (MIBC), but the role of locoregional therapy in survival remains unclear. The objective of this study was to compare overall survival (OS) between patients with MIBC who received trimodal therapy vs chemotherapy alone.</p> Methods <p>Patients diagnosed with MIBC between 2004 and 2021 were identified in the NCDB. The cohort was divided into those who received trimodal therapy vs chemotherapy only. Trimodal therapy included receipt of chemotherapy, surgery (modified radical or radical mastectomy), and radiation therapy. Overlap Propensity Score Weighted Cox proportional hazard models examined the association between treatment (chemotherapy versus trimodal therapy) and OS.</p> Results <p>A total of 2872 patients with MIBC were included, of whom 403 (14.0%) underwent trimodal therapy and 2469 (86.0%) received chemotherapy alone. Median OS was longer with trimodality therapy than with chemotherapy alone (47.0&#xa0;months vs 34.4&#xa0;months, <i>p</i> &lt; 0.001). Receiving trimodal therapy was associated with a 28% lower hazard of mortality compared to chemotherapy only (aHR: 0.72, 95% CI 0.62–0.84).</p> Conclusions <p>In this NCDB cohort of patients with MIBC, receipt of trimodal therapy improved OS compared with chemotherapy only.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Trimodal therapy is associated with higher overall survival than chemotherapy only in patients with metastatic inflammatory breast cancer

  • 期刊论文

  • 发表日期：

    2025年12月16日

查看全文
  • Eric Schupp,
  • Yevgeniya Gokun,
  • Jacob Eckstein,
  • Daniel G. Stover,
  • Sachin Jhawar,
  • Dionisia Quiroga,
  • Margaret E. Gatti-Mays,
  • Mathew Cherian,
  • Min-Jeong Cho,
  • Kai C. C. Johnson,
  • Heather LeFebvre,
  • JC Chen,
  • Mohamed I. Elsaid,
  • Samilia Obeng-Gyasi

摘要

Purpose

Systemic therapy is standard for metastatic inflammatory breast cancer (MIBC), but the role of locoregional therapy in survival remains unclear. The objective of this study was to compare overall survival (OS) between patients with MIBC who received trimodal therapy vs chemotherapy alone.

Methods

Patients diagnosed with MIBC between 2004 and 2021 were identified in the NCDB. The cohort was divided into those who received trimodal therapy vs chemotherapy only. Trimodal therapy included receipt of chemotherapy, surgery (modified radical or radical mastectomy), and radiation therapy. Overlap Propensity Score Weighted Cox proportional hazard models examined the association between treatment (chemotherapy versus trimodal therapy) and OS.

Results

A total of 2872 patients with MIBC were included, of whom 403 (14.0%) underwent trimodal therapy and 2469 (86.0%) received chemotherapy alone. Median OS was longer with trimodality therapy than with chemotherapy alone (47.0 months vs 34.4 months, p < 0.001). Receiving trimodal therapy was associated with a 28% lower hazard of mortality compared to chemotherapy only (aHR: 0.72, 95% CI 0.62–0.84).

Conclusions

In this NCDB cohort of patients with MIBC, receipt of trimodal therapy improved OS compared with chemotherapy only.